On Feb. 15, 2011, Sanofi-aventis announced it would acquired Genzyme for $74 a share in cash or $21.1 billion, and a tradable contingent value right (CVR) whose value will depend on Genzyme’s experimental multiple sclerosis drug Lemtrada and production of two other medicines. The CVR CVR ran through 2020.